Skip to main content

TAK-788-3001 A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

NCT04129502

A Randomized Phase 3 Multicenter Open-label Study to Compare the Efficacy of TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Takeda Pharmaceutical Company

The purpose of this study is to determine how safe and how well TAK-788 works as an initial therapy in patients with NSCLC with EGFR exon 20 insertion mutations; the results in these patients will be compared with results in patients receiving standard-of-care chemotherapy (platinum-doublet chemotherapy).

This study is currently enrolling.